European countries suspend use of AstraZeneca COVID-19 vaccine as regulators investigate blood clot reports
Regulators stress temporary halt is precautionary measure and that there is currently no evidence linking the shot to adverse events
Several European countries have suspended the use of AstraZeneca and Oxford University’s COVID-19 vaccine while the European Medicines Agency and other European drug regulators investigate a potential link to reports of blood clots in patients.
Austria suspended the use of a batch of the vaccine after a person was diagnosed with multiple thrombosis and died ten days after vaccination, while another is recovering after being hospitalised with pulmonary embolism.
And after the report of the death of a person in Denmark, the Danish Health Authority said on Thursday that “based on a precautionary principle” it had decided to stop use of the AstraZeneca/Oxford shot for 14 days while it carried out a full investigation.
Søren Brostrøm, Director General of the Danish Health Authority said that there was strong evidence that the vaccine is both safe and efficacious.
“However, The Danish Health Authority and the Danish Medicines Agency have to react promptly to reports from Denmark and other European countries of possible severe side effects. This is a clear indication that the monitoring system works,” he added.
Four other European member states – Estonia, Lithuania, Luxembourg and Latvia – as well as Iceland and Norway, have stopped administering the vaccine.
And the Italian Medicines Agency (AIFA) banned the use of a batch of the AstraZeneca vaccine due to “serious adverse events” after inoculation, although it stressed that at present there is no proven connection between vaccination and the adverse reactions.
In a statement, the agency said the ban targets batch ABV2856, and that it may consider additional measures, if needed, in coordination with the EMA.
The European Medicines Agency, which evaluates medicinal products across the 27-member state bloc, said there was currently no indication that vaccination with the shot had caused the conditions, which are not listed as side effects from the AstraZeneca vaccine.
“The position of EMA’s safety committee PRAC is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing,” the agency said. “PRAC is already reviewing all cases of thromboembolic events, and other conditions related to blood clots, reported post-vaccination with COVID-19 Vaccine AstraZeneca.”
In a statement regarding the Austria case earlier in the week, AstraZeneca said its vaccine is subject to strict and rigorous quality controls, and that there have been “no confirmed serious adverse events associated with the vaccine.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance